DEA Shuts Down Maui Pharmacy Over Controlled Substance Goofs
Published Date: 10/9/2026
Notice
Summary
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
DEA revokes Maui Clinic Pharmacy registration
DEA revoked L Krenk DBA Maui Clinic Pharmacy's Certificate of Registration No. BL3161178, so the Kahului, Hawaii location (22 Hana Highway, Suite B, Kahului, HI 96732) can no longer legally dispense controlled substances. The revocation is effective November 9, 2026.
Pending renewals and new registrations denied
The Order also denies any pending applications by L Krenk DBA Maui Clinic Pharmacy to renew or modify DEA registration No. BL3161178 and denies any pending application for additional registration in Hawaii. That denial is part of the same final Order effective November 9, 2026.
Audit found 4,779 unaccounted dosage units
An accountability audit for May 1, 2023 through July 9, 2024 found 4,779 unaccounted-for dosage units at the pharmacy: 1,804 Schedule II units, 708 Schedule III units, and 2,267 Schedule IV units. The DEA cited these recordkeeping and inventory discrepancies as violations of federal requirements and relied on them in revoking the registration.
Registrant deemed in default after missing hearing deadline
DEA served an Order to Show Cause on the pharmacy's owner on November 21, 2025; the registrant did not request a hearing within 30 days and was deemed in default, which meant the factual allegations in the OSC were admitted and became the basis for revocation. The final decision was signed October 5, 2026 and published October 9, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20748, Schedules of Controlled Substances: Placement of O-Desmethyltramadol in Schedule I; Correction
The DEA fixed a small mistake in their August 2026 rule that put O-desmethyltramadol and all its related forms into Schedule I, meaning it's now officially a highly controlled substance. This correction makes sure every version of the drug is covered, starting retroactively from August 12, 2026, through August 12, 2028. Anyone handling this drug should know it’s tightly regulated now, with no changes to fees but serious legal controls in place.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
Previous / Next Documents
Previous: 2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
Next: 2026-20751, Alexandra R. Lovec, A.P.R.N.; Decision and Order
Alexandra R. Lovec, a nurse practitioner in Montana, lost her DEA registration because she wrote prescriptions for strong drugs without proper medical reasons or patient checks. This means she can no longer legally prescribe controlled substances, protecting public safety. The decision took effect after a government review found repeated violations from 2022 to 2025.